Company intelligence / Profile preview

Altoida

Ownership: Private
Development stage: Preclinical

Overview

The company’s digital platform has been validated in research settings with nearly 20,000 participants and tens of thousands of assessments. It has shown promise in early detection of MCI and Alzheimer’s using a self-administered AR-based test that correlates with standard neuropsychological tests. The device has received FDA Breakthrough Device Designation but remains investigational pending regulatory clearance.

Therapeutic areas: PsychiatryNeurology
Modalities: Device (digital diagnostic platform)Non-pharmacological therapy (digital cognitive assessment)Artificial intelligence-based diagnosticsAugmented reality-based diagnostics
Industry: Digital Health Medical Devices

Partnerships

Research collaborations with global pharmaceutical leaders to support clinical trial enrichment and screening optimization; specific partners not named publicly as of June 2025.

Beyond the preview

Go deeper on Altoida.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altoida.

Explore the full profile